lifestyle.longislandreport.org

Author: Edgewise Therapeutics

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

April 1, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

March 10, 2026
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

March 4, 2026
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

March 3, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

March 2, 2026
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

February 26, 2026
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

February 11, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

February 2, 2026
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

January 13, 2026
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

January 6, 2026